Several infections start on mucosal surfaces. These results suggest that antigen-FLIPr fusion protein alone via intranasal administration can be applied to mucosal vaccine development. Furthermore, we employed immunodeficient AG129 mice as a Zika virus infection model and demonstrated that intranasal administration of recombinant Zika virus envelope protein domain III-FLIPr fusion protein induced protective immune responses against the Zika virus. Importantly, activation of OVA-specific CD4 + and CD8 + T cells and induction of a broad-spectrum cytokine secretion profile were detected after intranasal administration of rOVA-FLIPr alone in immunocompetent C57BL/6 mice. Subsequently, OVA-specific IgG and IgA antibodies in the circulatory system and IgA antibodies in mucosal tissue were detected. Our results demonstrate that intranasal administration of recombinant OVA-FLIPr fusion protein (rOVA-FLIPr) alone efficiently delivers OVA to DCs in nasal lymphoid tissue. We employed formyl peptide receptor-like 1 inhibitory protein (FLIPr), an FcγR antagonist secreted by Staphylococcus aureus, as a vector to target ovalbumin (OVA) to dendritic cells (DCs) via intranasal administration.
Please check the details below.Ming-Shu Hsieh 1, Chia-Wei Hsu 1, Ling-Ling Tu 1, Kit Man Chai 1, Li-Lu Yu 1, Chiao-Chieh Wu 1, Mei-Yu Chen 1, Chen-Yi Chiang 1, Shih-Jen Liu 1,2,3, Ching-Len Liao 1 and Hsin-Wei Chen 1,2,3*